Canaccord Genuity Group Forecasts Strong Price Appreciation for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock
Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) had its price target raised by Canaccord Genuity Group from $394.00 to $420.00 in a research report released on Friday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Several other research firms have also recently weighed in on MDGL. Citigroup increased their price target on […]
Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) had its price target raised by Canaccord Genuity Group from $394.00 to $420.00 in a research report released on Friday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Several other research firms have also recently weighed in on MDGL. Citigroup increased their price target on […]
